This proposal for a Specialized Program of Research Excellence (SPORE) in Breast Cancer at The Johns Hopkins Medical Institutions brings together a highly interactive, multi-disciplinary program of translational research in breast cancer. The SPORE includes four research programs with seven integrated projects spanning the fields of risk assessment, diagnosis, staging, treatment, and prevention. Program 1, Development of molecular markers to define breast cancer progression and classification. Project 1A, Molecular markers for breast cancer (Saraswati Sukumar Ph.D.), Project 1B, Molecular phenotypes of breast cancer (Edward Gabrielson M.D.). Program 2 Project 2A, Molecular detection of breast cancer (James Herman M.D.). Program 3, Development of molecular strategies for breast cancer therapy and prevention. Project 3A, Novel polyamine analogs for breast cancer treatment (Robert Casero Ph.D.); Project 3B, Use of demethylating and histone deacetylating agents to treat breast cancer (Nancy Davidson agents to treat breast cancer (Nancy Davidson, M.D.); Project 3C, Vaccines: A new paradigm for breast cancer prevention (Elizabeth Jaffee, M.D.). Program 4 Project 4A, Molecular epidemiology of progression to breast cancer (Kathy Helzlsour M.D., MHC). These seven research projects are supported by three cores: Core 1, Administration and communications (Nancy Davidson, M.D.). Core 2, Human specimen resource and database (Mark Sherman M.D.) To facilitate career development of individuals with an interest in translational breast cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA088843-01
Application #
6224861
Study Section
Special Emphasis Panel (ZCA1-GRB-V (O1))
Program Officer
Kuzmin, Igor A
Project Start
2000-09-30
Project End
2005-09-29
Budget Start
2000-09-30
Budget End
2001-09-29
Support Year
1
Fiscal Year
2000
Total Cost
$2,699,321
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lo, Pang-Kuo (2018) FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends Diabetes Metab 1:
Cravero, Karen; Medford, Arielle; Pallavajjala, Aparna et al. (2018) Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Pract Lab Med 12:e00108
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Lo, Pang-Kuo (2017) The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open 1:
Haffner, Michael C; Esopi, David M; Chaux, Alcides et al. (2017) AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun 8:142
Sunay, Melek M E; Foote, Jeremy B; Leatherman, James M et al. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 46:112-123
Parsons, Heather A; Beaver, Julia A; Cimino-Mathews, Ashley et al. (2017) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:379-386
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc et al. (2016) Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7:6281-93
Lo, Pang-Kuo; Lee, Ji Shin; Liang, Xiaohui et al. (2016) The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. Cell Signal 28:1502-19

Showing the most recent 10 out of 282 publications